Publications by authors named "Kathleen Tenner"

Claim this Profile
P
Pembrolizumab in Combination with Binimetinib in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer.
Saranya Chumsri, Joseph J Larson, Emily Liu, Kathleen S Tenner, Daniel Adams

Clin Cancer Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer.
Jodi M Carter, Saranya Chumsri, Douglas A Hinerfeld, Yaohua Ma, Xue Wang, Kathleen S Tenner

Nat Commun· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials.
Saranya Chumsri, Zhuo Li, Daniel J Serie, Nadine Norton, Afshin Mashadi-Hossein, Kathleen Tenner

NPJ Breast Cancer· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).
Michael Gnant, Amylou C Dueck, Sophie Frantal, Miguel Martin, Hal J Burstein, Kathleen Tenner

J Clin Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy.
Mei-Yin C Polley, Maura N Dickler, Jason Sinnwell, Kathleen Tenner, Juan de la Haba

Breast Cancer Res Treat· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance).
Tufia C Haddad, Jun He, Ciara C O'Sullivan, Beiyun Chen, Donald Northfelt, Kathleen S Tenner

Breast Cancer Res Treat· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study.
Carlos E Vargas, Cameron S Thorpe, Amylou C Dueck, Kathleen S Tenner, Nancy E Davidson

Cancer· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer.
Nadine Norton, Nicholas Fox, Christie-Ann McCarl, Kathleen S Tenner, Karla Ballman

Breast Cancer Res· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2 Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831.
Monica M Reinholz, Beiyun Chen, Amylou C Dueck, Kathleen Tenner, Karla Ballman

Clin Cancer Res· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial.
Edith A Perez, Karla V Ballman, Afshin Mashadi-Hossein, Kathleen S Tenner, Jennifer M Kachergus

J Natl Cancer Inst· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines.
Mithun Vinod Shah, Anne E Wiktor, Reid G Meyer, Kathleen S Tenner, Karla V Ballman

J Clin Oncol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain.
Keith L Knutson, Raphael Clynes, Barath Shreeder, Patrick Yeramian, Kathleen P Kemp, Kathleen S Tenner

Cancer Res· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.
Edith A Perez, E Aubrey Thompson, Karla V Ballman, S Keith Anderson, Yan W Asmann, Kathleen S Tenner

J Clin Oncol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831.
Nadine Norton, Rebecca M Olson, Mark Pegram, Kathleen Tenner, Karla V Ballman

Cancer Immunol Res· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.
Amylou C Dueck, Monica M Reinholz, Xochiquetzal J Geiger, Kathleen Tenner, Karla Ballman

Clin Cancer Res· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.
Alvaro Moreno-Aspitia, David W Hillman, Stephen H Dyar, Kathleen S Tenner, Julie Gralow

Cancer· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.
Alvaro Moreno-Aspitia, Amylou C Dueck, Ismael Ghanem-Cañete, Tejal Patel, Shaker Dakhil, Kathleen S Tenner

Breast Cancer Res Treat· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.
Edith A Perez, Amylou C Dueck, Ann E McCullough, Monica M Reinholz, Kathleen S Tenner

J Natl Cancer Inst· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437.
Monica M Reinholz, Kathleen A Kitzmann, Kathleen Tenner, David Hillman, Amylou C Dueck

Clin Cancer Res· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial.
Edith A Perez, Monica M Reinholz, David W Hillman, Kathleen S Tenner, Matthew J Schroeder

J Clin Oncol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis